CONTEXT AND OBJECTIVE: To examine stroke risk factors, including atrial fibrillation, management and prevention, and stroke outcomes across Latin America. DESIGN AND SETTING: Narrative review conducted at Piedmont Heart Institute, United States. 
INTRODUCTION
Stroke is a serious challenge in Latin America and throughout the world. The Global Burden of Disease (GBD) study estimated that in 2013 there were approximately 26 million stroke survivors worldwide, 71% of whom had experienced ischemic strokes. 1 In the same year, 10.3 million people experienced new strokes (67% consisting of ischemic stroke) and 6.5 million people died from stroke (51% consisting of ischemic stroke). 1 Two-thirds of all strokes occur in low and middle-income countries, 2, 3 as categorized by the World Bank, which include most of Latin America. [3] [4] [5] Continuing studies will help to clarify the complexities of stroke epidemiology. [6] [7] [8] [9] According to the most recent figures available from the PanAmerican Health Organization (PAHO) for the Americas region, cardiovascular diseases accounted for 1.6 million deaths in 2012, of which 22% were due to cerebrovascular diseases (ahead of heart failure and hypertension, each with 9% of the total). 10 A similar pattern was observed throughout the region, with some variations. For example, 31% of cardiovascular deaths in Brazil were attributed to cerebrovascular diseases. 10 The GBD investigators noted that agestandardized stroke incidence, mortality, prevalence and strokerelated disability declined from 1990 to 2013. 1 However, over the same period, the absolute number of people affected by stroke increased considerably across the globe, suggesting that the worldwide stroke burden continues to increase due to population growth and aging. 1 Although most of the burden of stroke is borne by low-and middle-income countries, stroke incidence rates have fallen concomitantly with reductions in risk factors associated with stroke therapies in high-income countries. 11 For instance, people in the United States had fewer strokes, and were less likely to die after strokes, in 2011 than in 1987. 12 PAHO/World Health Organization (WHO) age-adjusted estimates for cerebrovascular mortality by country in 2013 (except years as indicated) are shown in Figure 1 . 10 The GBD 2013 survey demonstrated that stroke was among the ten leading causes of disability-adjusted life-years (DALYs) in the majority of countries in Latin America and the Latin Caribbean, and was one of the five leading causes in most of them. 18 Atrial fibrillation is more common with increasing age:
75% of individuals with atrial fibrillation are aged ≥ 60 years. 18 Further, many cases of atrial fibrillation are not detected, and there is a clear need to improve the diagnosing of atrial fibrillation so as to reduce stroke risk in Latin American countries.
OBJECTIVES
Stroke is common but has been incompletely characterized across Latin America. An English-language literature review was conducted to identify the incidence and prevalence of stroke, the approaches to its management and prevention and patient outcomes across a range of countries in Latin America and the Caribbean, with particular attention to the association between stroke and nonvalvular atrial fibrillation, which is an important and underdiagnosed risk factor.
METHODS
Information for this narrative review was obtained through a systematic search of the literature to identify published English language scientific papers relating to the search terms. The search terms used were stroke AND "Latin America" AND epidemiology, covering the period and disposition of the initial structured search is shown in Figure 2 .
The results from the pivotal trials that demonstrated the efficacy and safety of four non-vitamin K antagonist oral anticoagulants that have been indicated for reducing the risk of stroke in patients with atrial fibrillation are summarized in Table 2 .
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Records after non-English language texts removed, n = 51 per-patient cost of hospitalization for ischemic stroke was $1,902 in Brazil versus $3,888 in Argentina for a similar mean duration of hospital stay: 13.3 and 13.0 days, respectively. 26, 27 The personal financial burden can be heavy for Latin Americans, many of whom incur high out-of-pocket healthcare costs.
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Health transitions
As the global threat of communicable diseases recedes, chronic and non-communicable conditions are taking their place. 13, 29 For Brazil overall, this shift occurred in the 1960s, but analysis confined to the major cities shows that cerebrovascular mortality rates began to exceed mortality from other cardiovascular conditions, such as rheumatic heart disease and syphilitic aortic disease, as early as the mid-1940s. 30 The GBD study in 2013 found that the leading risk factors threatening global health were those underlying non-communicable diseases, including stroke: high blood pressure, smoking, diet, obesity, elevated blood glucose, dyslipidemia, air pollution, and alcohol over-consumption. 13 Furthermore, Latin America is undergoing a transition in which, although deaths from chronic diseases now exceed deaths from infections and malnutrition for most of the region, residents of underserved regions still remain at risk of infections and malnutrition, which are associated with an elevated risk of stroke. 3, 6, 13 Hypertension is acknowledged to be the leading risk factor for stroke in Latin America, 2,11 but because hypertension and other preventable risk factors are amply covered in the literature, the Stroke-associated costs are substantial. National expenditure for ischemic stroke management in 2008 was US$ 326.9 and 239.9 million in Brazil and Argentina, respectively. 26, 27 The mean present review focused on atrial fibrillation, a less easily diagnosed but significant and treatable cause of ischemic stroke.
RESULTS
Stroke in Latin America
Poverty: a global risk factor for stroke
The Latin American/Caribbean region, like many others, has considerable economic inequality and a widening income gap. 6, 29 Stroke prevalence rates are higher in poorer areas than in more affluent areas. In a 2010 survey of low-income residents in São
Paulo aged > 35 years, 5.4% self-reported prior stroke. The age-adjusted prevalence rates for men and women were 4.6% and 6.5%, respectively, i.e. higher than those reported in many other countries. 31 Another study on low-income residents aged > 65 years in São Paulo found higher prevalence of coronary heart disease, left bundle-branch block and atrial fibrillation, consistent with the burden of stroke mortality in Brazil. 32 However, this disparity is not limited to urban areas, given that a 2011 survey of residents aged > 35 years in ribeirinha communities compared with urban residents of the same municipality found higher crude prevalence of stroke in rural areas (6.3 versus 3.7%, respectively) after adjustment for sex and age. 33 Despite trends showing declining stroke mortality rates across Brazil consistent with the worldwide trend, stroke mortality rates remain high among lowincome Brazilians and have not dramatically decreased over the last three decades. Reductions in stroke mortality over the last 20 years were greatest in the two wealthiest regions and least in the poorest regions. 34 The burden of stroke risk factors, and in particular, hypertension, has been characterized as a partial consequence of social determinants, including socioeconomic inequality and perceived discrimination. These are structural factors underlying global health inequalities that exceed the expected influence of access to health services. 30, 35, 36 Efforts to modify risk factors and alleviate the burden of stroke could be aided by economic and social improvements, including implementation of cost-effective public health policies. Enhanced surveillance efforts in outlier regions where there is a high stroke burden, particularly at low-and middle-income levels, could help to clarify factors implicated in the disproportionate stroke burden and guide interventions with specific goals. 
Atrial fibrillation
The principal mechanism for stroke in patients with atrial fibrillation is embolization of stasis-induced thrombi in the left atrial appendage. The risk of stroke in patients with atrial fibrillation increases with age and other risk factors, including hypertension, diabetes, heart failure and previous stroke. 16, 37 Strokes associated with atrial fibrillation are generally more severe, cause greater disability and are associated with worse outcomes than are strokes in patients without atrial fibrillation. 37 In a survey of seven countries in Latin America, more than half of the patients with atrial fibrillation were receiving medical treatment, but a significant proportion of the 60% treated as outpatients were not receiving appropriate anticoagulant therapy, despite having a high stroke risk. 18 Moreover, the proportion of patients with atrial fibrillation receiving treatment within the national healthcare system decreased with increasing age across all countries. Cost and lack of health infrastructure are major barriers to care, and suboptimal care is associated with poor outcomes. 1, 3, 6 The Mexican PREMIER registry investigators urged secondary prevention to modify stroke risk factors, including atrial fibrillation.
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Guidelines and management initiatives
Patients with atrial fibrillation are an important target for efforts to reduce the risk of stroke through anticoagulant therapy. Vitamin K antagonists, such as warfarin, phenprocoumon and acenocoumarol, are widely prescribed in Latin America.
Compared with no therapy, vitamin K antagonists reduce the risk of stroke by 62-68% and the rate of death by 26-33%. 37 For every 1,000 patients adequately treated with warfarin, 31 ischemic strokes are prevented each year. 39 Globally, fewer than half of patients with atrial fibrillation receive adequate anticoagulation to reduce the risk of embolic stroke. 40 The Acute Decompensated Heart Failure National Registry (ADHERE), which enrolled patients with decompensated heart failure and either new-onset or a history of atrial fibrillation in 10 countries across Latin America/Asia-Pacific, found that prophylactic anticoagulation was underused, with significant differences in use among the participating countries. 41 Since 2006, the Chilean Ministry of Health national guidelines have guaranteed a minimum level of care for every patient with ischemic stroke, with assurance of rapid neurological assessment, computed tomography scans, hospitalization, neurorehabilitation and secondary prevention. 6 At a Cuban stroke center, a 10-component fast-track approach doubled hospital admission rates and halved case-fatality rates in the region from 1990 to 2003. 46 Many hospitals have established stroke units, which increase the likelihood of good outcomes, although stroke units are yet to be adopted as national health care policy by any regional government. 6 Practices at a comprehensive care center in Brazil changed following a retrospective study showing that adequate oral anticoagulation for patients with atrial fibrillation could have prevented half of all strokes. 47 However, another survey at a tertiary care clinic in São
Paulo showed that only 55% of patients with atrial fibrillation and high stroke risk received dose-adjusted warfarin. 48 In a Mexican cohort, fewer than half of patients with nonvalvular atrial fibrillation and cerebral infarction were discharged with an oral anticoagulant; patients who lived in rural areas or had functional impairment on discharge were least likely to be prescribed warfarin. trial, there were more than 21,000 patients with nonvalvular atrial fibrillation, including 2,661 from Latin America. 23 In the pivotal trials, primary efficacy and safety findings were consistent across subgroups, including those in Latin America and other geographic regions worldwide. [19] [20] [21] [22] [23] Non-vitamin K antagonist oral anticoagulants are easier to use than warfarin, are at least as effective and are associated with lower rates of intracranial hemorrhage. [19] [20] [21] [22] [23] Acquisition costs for these drugs are higher than for warfarin, but a cost-benefit review of treatment for atrial fibrillation, based on observational studies, suggested that the overall cost of therapy may be lower because, in contrast to warfarin, dose adjustment and routine monitoring of the anticoagulant effect are not required, and the risk of complications from therapy over the long term may be lower. 51 However, cost-effectiveness comparisons of non-vitamin K antagonist agents versus warfarin are warranted before the results can be directly applied to the real-world setting. 
CONCLUSIONS
This narrative review draws on the current literature, including systematic reviews by several investigators, and thus does not report original findings or any results from systematic analysis.
Nonetheless, the consensus from this review of the literature indicates that greater awareness and further studies, resources and actions are needed to reduce the heavy and growing burden of stroke in Latin America.
